

Assessment of different doses of polyphenols from dealcoholized red wine and red wine on blood pressure and endothelial function in subjects with metabolic syndrome and high cardiovascular risk.

Submission date 31/07/2015	Recruitment status No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered
Registration date 18/09/2015	Overall study status Completed	<input type="checkbox"/> Protocol
Last Edited 18/09/2015	Condition category Nutritional, Metabolic, Endocrine	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

Antioxidants are substances, natural or man-made, that may prevent or delay damage to the cells in our bodies. They are found in many foods, including fruit and vegetables. Polyphenols are the most abundant antioxidants in the diet and are found in a wide variety of foods in nature. One of the foods most rich in these compounds is wine. It has been considered that the biological effects of these compounds depend on their bioavailability (the amount of the compound made available to the body after digesting) and kinetics of its exposure time in the human body. Many studies have found that moderate wine drinkers have a lower cardiovascular mortality and a lower incidence of myocardial infarction and stroke, among others. The aim of this study is to assess the usefulness of phenolic metabolites as specific biomarkers of wine consumption and observe whether the ethanol increases the bioavailability of phenolic compounds.

Who can participate?

Participants between 55 and 80 years of age without a history of cardiovascular disease, any of several chronic diseases or an allergy/intolerance to and grape and wine. They should also have at least 3 of the following: high blood pressure (hypertension), high blood glucose levels or needing to use antidiabetic drugs/insulin, high blood triglyceride and cholesterol levels and a waist circumference of at least 102cm for men and 88cm for women.

What does the study involve?

Participants are randomly allocated into one of 4 groups. Those in group 1 are asked to drink 375 mL/day of extra water for three months. Those in group 2 are asked to drink 375 mL/day of dealcoholized red wine for three months. Those in group 3 are asked to drink 375 mL/day of dealcoholized red wine enriched with a grape extract for three months. Women in group 4 are asked to drink 130 mL/day of red wine. Men in group 4 are asked to drink 260 mL/day of wine for

men for three months. All participants are requested to avoid consuming grape, wine and other alcoholized drinks for the 15 days leading up to the start of the study. All participants have a medical assessment at the start and end of the study, which includes clinical history, dietary evaluation, anthropometric (body) measures, clinical blood pressure and 24-hour ambulatory blood pressure (that is, blood pressure taken over a 24 hour period as the participant goes about their daily activities), measurement of blood flow in brachial artery (major blood vessel in upper arm), full blood analysis (glucose, glycated hemoglobin, triglycerids, total cholesterol, HDLc, LDLc, lipoprotein (a)) and the collection of 24-hour urine sample.

What are the possible benefits and risks of participating?

There are no risks as long as the exclusion criteria are followed.

Where is the study run from?

The Department of Nutrition and Food Science of the University of Barcelona and the Department of Internal Medicine in the Hospital Clinic of Barcelona (Spain)

When is the study starting and how long is it expected to run for?

July 2015 to July 2016

Who is funding the study?

1. Ministry of Economy and Competitiveness, MINECO
2. Biomedical Research Centre in Physiopathology of Obesity and Nutrition (Ciberobn)

Main contact

Dr. Rosa Lamuela-Raventós

Contact information

Type(s)

Public

Contact name

Dr Rosa M. Lamuela-Raventós

ORCID ID

<https://orcid.org/0000-0002-1287-4560>

Contact details

Food Science Department, Pharmacy Faculty, University of Barcelona

Av/ Joan XXIII S/N

Barcelona

Spain

08028

Additional identifiers

Protocol serial number

IRB00003099

Study information

Scientific Title

Effects of bioactive compounds of dealcoholized red wine with two different polyphenol doses and red wine on blood pressure, biochemical parameters and cellular biomarkers related to atherosclerosis in subjects with metabolic syndrome. An open, randomized, parallel and controlled trial.

Acronym

POLYREDWIMES

Study objectives

Wine contains several phenolic compounds, which are known for its health benefits.

Aim 1: Compare the effects of consumption of dealcoholized red wine and dealcoholized red wine enriched with grape extract on anthropometric parameters, blood pressure, full blood analysis, levels of endothelial biomarkers and leukocyte cell-surface adhesion molecules in the subjects.

Aim 2: Compare the effects between dealcoholized red wine and regular alcoholized red wine on full blood analysis in subjects, anthropometric parameters, endothelial biomarkers, blood pressure and other cardiovascular risk factors.

Ethics approval required

Old ethics approval format

Ethics approval(s)

University of Barcelona is Jordi Alberch Viè, 11/12/2014, ref: IRB00003099

Study design

Dietary intervention trial, parallel, randomized, open and controlled

Primary study design

Interventional

Study type(s)

Prevention

Health condition(s) or problem(s) studied

Metabolic Syndrome (MeTS)

Interventions

Participants are randomly allocated into one of 4 groups.

Intervention 1: 375 mL/day of extra water for three months (ICT).

Intervention 2: 375 mL/day of dealcoholized red wine for three months (IVS).

Intervention 3: 375 mL /day of dealcoholized red wine enriched with a grape extract for three months (IVE).

Intervention 4: 130 mL/day of red wine for women and 260 mL/day of wine for men during three months (IVI).

Intervention Type

Primary outcome(s)

1. Leukocyte adhesion molecule expression: lymphocyte and monocyte adhesion molecules on these cells will be marked with monoclonal antibodies (MAb) conjugated with fluorescein-isothiocyanate (FITC) and phycoerythrin (PE) by direct double immunofluorescence. The MAb of the adhesion molecules used will be: anti-CD11a (LFA-1), anti-CD40L, anti-CD11b (Mac-1) (Bender MedSystems Diagnostics, Vienna), anti-Syalil Lewis (anti-CD15s) (Pharmingen, San Diego, CA), anti-CD49d (VLA-4) (Cytogmos). The monoclonal antibodies used to mark the T-lymphocytes will be anti-CD2 and monocytes, anti-CD14 (Caltag Laboratories, Burlingame, CA).
 2. Decrease in the endothelial adhesion molecules, chemokines and interleukins with the increase in phenolic content of the treatment (IVI > IVE > IVS > ICT).
 3. Improvement of endothelial function in all interventions, measuring endothelial progenitor cells and circulating endothelial cells.
- All variables (primary and secondary outcomes) will be measured at baseline and after each intervention period.

Key secondary outcome(s)

1. All participants in the study will be clinically examined and subsequently signed an informed consent according accept their participation in the study
2. At the beginning and end of each intervention period a medical assessment will be performed which included: clinical history, dietary evaluation, anthropometric measures, clinical blood pressure and 24-hour ambulatory blood pressure, measurement of blood flow in brachial artery, full blood analysis (glucose, glycated hemoglobin, triglycerids, total cholesterol, HDLc, LDLc, lipoprotein (a)) and the collection of 24-h urine sample.
3. A 7-day food record validated nutritional questionnaire will be used at the beginning and end of the intervention to assess nutrient intake and to monitor adherence to the dietary recommendations. We will use the Food Processor Nutrition & Fitness software. Physical activity will also be evaluated with the Minnesota Leisure Time Physical Activity questionnaire which has also been validated in Spain
4. Bioavailability, identification and quantification polyphenols in plasma and urine to determine and compared new metabolites by LTQ-Orbitrap Mass Spectrometry and HPLC-MS/MS
5. Changes in urine metabolites (metabolomics)

Completion date

31/10/2016

Eligibility

Key inclusion criteria

Participants between 55 and 80 years of age and showed ≥ 3 of the following parameters that define the metabolic syndrome:

1. Hypertension ($\geq 130/85$ mm Hg or use of antihypertensive drugs)
2. Impaired glucose tolerance (glycemia ≥ 100 mg/dL or use of antidiabetic drugs and/or insulin)
3. Serum triglyceride concentration ≥ 150 mg/dL
4. Plasma HDL cholesterol concentrations ≤ 40 mg/dL (men), ≤ 50 mg/dL (women)
5. Waist circumference ≥ 102 cm (men), ≥ 88 cm (women)

Participant type(s)

Other

Healthy volunteers allowed

No

Age group

Mixed

Sex

All

Key exclusion criteria

Healthy adults (males and females) or with:

1. Previous history of cardiovascular disease
2. Any several chronic diseases
3. Grape and wine intolerance or allergic
4. Alcoholism
5. Other toxic abuse

Date of first enrolment

01/10/2015

Date of final enrolment

31/07/2016

Locations**Countries of recruitment**

Spain

Study participating centre

Department of Nutrition and Food Science of the University of Barcelona (Barcelona, Spain) and the Department of Internal Medicine in the Hospital Clinic of Barcelona.

Barcelona

Spain

08028

Sponsor information**Organisation**

Bodegas Torres

Organisation

Biomedical Research Centre in Physiopathology of Obesity and Nutrition (Ciberobn)

Organisation

Ministry of Economy and Competitiveness

Funder(s)**Funder type**

Government

Funder Name

Ministerio de Economía y Competitividad

Alternative Name(s)

Ministry of Economy and Competitiveness, MINECO, MEC

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

Spain

Funder Name

Biomedical Research Centre in Physiopathology of Obesity and Nutrition (Ciberobn)

Results and Publications**Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not expected to be made available